Editas Medicine Inc

Stock Chart, Company Information, and Scan Results

$2.80(as of Aug 22, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Editas Medicine Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$2.80
Ticker SymbolEDIT
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees246
CountyUSA
Market Cap$245.5M
EBIDTA-154.1M
10-Day Moving Average2.71
P/E Ratio-1.00
20-Day Moving Average2.63
Forward P/E Ratio0.00
50-Day Moving Average2.62
Earnings per Share-2.84
200-Day Moving Average1.90
Profit Margin-1,487.84%
RSI53.45
Shares Outstanding89.9M
ATR0.25
52-Week High4.12
Volume1,466,502
52-Week Low0.91
Most Recent Support Level2.60
Book Value19.2M
Most Recent Resistance Level3.17
P/B Ratio12.32
Upper Keltner3.18
P/S Ratio6.08
Lower Keltner2.07
Debt-to-Equity Ratio3.18
Next Earnings Date11/10/2025
Cash Surplus72.6M
Next Ex-Dividend DateUnknown

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Editas Medicine Inc In Our Stock Scanner

As of Aug 22, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.